Ellume, an Australian company that manufactures a 15-minute at-home test for the coronavirus, has agreed to a $231.8 million deal with the Biden administration has made a $231.8 million deal with an Australian company to boost availability of the first at-home rapid test for the coronavirus.
The Ellume test, which is available without a prescription, can send results to a smartphone within 15 minutes of receiving a sample.
The Food and Drug Administration gave emergency authorization to Ellume’s rapid test in December, after it showed 96% accuracy in a U.S. clinical study. Those trials included both adults and children of ages 2 years and older.
Read the full story via NPR.
